FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
Hosted on MSN1mon
Johnson & Johnson sues Cigna units for alleging draining funds intended for copays: report
Johnson & Johnson (NYSE ... According to the report, J&J added Cigna’s Express Scripts pharmacy benefits manager and specialty pharmacy Accredo as defendants in an amended lawsuit it filed ...
Forbes1y
Johnson And Johnson Stock Slips After Missing The Mark For Earnings
Johnson and Johnson revealed lower earnings and sales numbers than expected in Q4 2022 Even before Q4 numbers were released, JNJ started falling after a slew of new stories hit the press Even ...